134 related articles for article (PubMed ID: 12010799)
21. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect.
Nogami K; Shima M; Nakai H; Tanaka I; Suzuki H; Morichika S; Shibata M; Saenko EL; Scandella D; Giddings JC; Yoshioka A
Br J Haematol; 1999 Oct; 107(1):196-203. PubMed ID: 10520041
[TBL] [Abstract][Full Text] [Related]
22. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex.
Amano K; Arai M; Koshihara K; Suzuki T; Kagawa K; Nishida Y; Fukutake K
Am J Hematol; 1995 Aug; 49(4):310-7. PubMed ID: 7639276
[TBL] [Abstract][Full Text] [Related]
23. Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor.
Raut S; Villard S; Grailly S; Gilles JG; Granier C; Saint-Remy JM; Barrowcliffe TW
Thromb Haemost; 2003 Sep; 90(3):385-97. PubMed ID: 12958606
[TBL] [Abstract][Full Text] [Related]
24. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation.
Fay PJ; Coumans JV; Walker FJ
J Biol Chem; 1991 Feb; 266(4):2172-7. PubMed ID: 1846615
[TBL] [Abstract][Full Text] [Related]
25. Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.
Castro-Núñez L; Bloem E; Boon-Spijker MG; van der Zwaan C; van den Biggelaar M; Mertens K; Meijer AB
J Biol Chem; 2013 Jan; 288(1):393-400. PubMed ID: 23168412
[TBL] [Abstract][Full Text] [Related]
26. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.
Precup JW; Kline BC; Fass DN
Blood; 1991 May; 77(9):1929-36. PubMed ID: 1902121
[TBL] [Abstract][Full Text] [Related]
27. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
Scandella D; Gilbert GE; Shima M; Nakai H; Eagleson C; Felch M; Prescott R; Rajalakshmi KJ; Hoyer LW; Saenko E
Blood; 1995 Sep; 86(5):1811-9. PubMed ID: 7544643
[TBL] [Abstract][Full Text] [Related]
28. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
[TBL] [Abstract][Full Text] [Related]
29. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
Shima M; Yoshioka A; Nakajima M; Nakai H; Fukui H
Br J Haematol; 1992 Aug; 81(4):533-8. PubMed ID: 1390241
[TBL] [Abstract][Full Text] [Related]
30. Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.
Layet S; Girma JP; Obert B; Peynaud-Debayle E; Bihoreau N; Meyer D
Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):129-37. PubMed ID: 1531749
[TBL] [Abstract][Full Text] [Related]
31. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.
Fricke WA; Brinkhous KM; Garris JB; Roberts HR
Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998
[TBL] [Abstract][Full Text] [Related]
32. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
[TBL] [Abstract][Full Text] [Related]
33. Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to platelets.
Goudemand J; Mazurier C; Samor B; Bouquelet S; Montreuil J; Goudemand M
Thromb Haemost; 1985 Jun; 53(3):390-5. PubMed ID: 2864750
[TBL] [Abstract][Full Text] [Related]
34. Immunologic studies of native and modified human factor VIII/von Willebrand factor.
Switzer ME; McKee PA
Blood; 1979 Aug; 54(2):310-21. PubMed ID: 88237
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
36. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
37. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.
Nogami K; Shima M; Giddings JC; Takeyama M; Tanaka I; Yoshioka A
Int J Hematol; 2007 May; 85(4):317-22. PubMed ID: 17483075
[TBL] [Abstract][Full Text] [Related]
38. Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor.
Lavergne JM; Piao YC; Ferreira V; Kerbiriou-Nabias D; Bahnak BR; Meyer D
Biochem Biophys Res Commun; 1993 Aug; 194(3):1019-24. PubMed ID: 8352759
[TBL] [Abstract][Full Text] [Related]
39. Role of factor VIII C2 domain in factor VIII binding to factor Xa.
Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A
J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497
[TBL] [Abstract][Full Text] [Related]
40. The association of factor VIII with von Willebrand factor.
Lollar P
Mayo Clin Proc; 1991 May; 66(5):524-34. PubMed ID: 1903173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
